Inovio’s FDA clock is almost up | Lattice Finance Blog

Inovio’s FDA clock is almost up thumbnail

The countdown is on

Inovio Pharmaceuticals is staring down an October 30 PDUFA date for INO-3107, its lead DNA medicine candidate for recurrent respiratory papillomatosis, or RRP. In plain English: the FDA has a deadline, and Inovio is waiting to see whether its shot at turning a niche but nasty disease into a commercial product gets a green light.

Why investors care

This is classic biotech popcorn. You don’t need a dozen moving parts here — just one big FDA decision that could either validate the platform or send traders reaching for the exit. For a small biotech, a single ruling can matter more than a whole year of conference-circuit optimism.

What’s at stake

If INO-3107 gets approved, Inovio gets a real shot at making RRP more than a clinical footnote. If it doesn’t, the market will probably treat the program like a pothole at the worst possible time.

Big picture

Biotech stocks live and die by calendar dates, and this one’s a biggie. The closer you get to the decision, the more the stock can behave like a roulette wheel in a lab coat.